Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J Morgan

Showing results (251-260 of 267) with videos related to

Pageof 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trialG Somlo, J H Doroshow, A Lev-Ran, et al.
Cancer Research|May 1, 1992
Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancerE M Newman, S A Akman, J S Harrison, et al.
Applied Occupational and Environmental Hygiene|May 15, 2003
Workplace airborne hexavalent chromium concentrations for the Painesville, Ohio, chromate production plant (1943-1971)D M Proctor, J P Panko, E W Liebig, et al.
Gynecologic Oncology|June 1, 2000
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-upR J Morgan, P Braly, L Leong, et al.
Cancer Chemotherapy and Pharmacology|July 27, 2000
Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosisM L Tetef, K A Margolin, J H Doroshow, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2001
Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapyR J Morgan, T Synold, B I Carr, et al.
Bone Marrow Transplantation|January 10, 2002
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancerR J Morgan, J H Doroshow, L Leong, et al.
Cancer Chemotherapy and Pharmacology|December 29, 2000
A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine AJ W Raschko, T W Synold, W Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell supportR J Morgan, J H Doroshow, K Venkataraman, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumorsE M Newman, M Carroll, S A Akman, et al.
Pageof 27

Showing results (251-260 of 267) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trialG Somlo, J H Doroshow, A Lev-Ran, et al.
Cancer Research|May 1, 1992
Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancerE M Newman, S A Akman, J S Harrison, et al.
Applied Occupational and Environmental Hygiene|May 15, 2003
Workplace airborne hexavalent chromium concentrations for the Painesville, Ohio, chromate production plant (1943-1971)D M Proctor, J P Panko, E W Liebig, et al.
Gynecologic Oncology|June 1, 2000
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-upR J Morgan, P Braly, L Leong, et al.
Cancer Chemotherapy and Pharmacology|July 27, 2000
Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosisM L Tetef, K A Margolin, J H Doroshow, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2001
Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapyR J Morgan, T Synold, B I Carr, et al.
Bone Marrow Transplantation|January 10, 2002
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancerR J Morgan, J H Doroshow, L Leong, et al.
Cancer Chemotherapy and Pharmacology|December 29, 2000
A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine AJ W Raschko, T W Synold, W Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell supportR J Morgan, J H Doroshow, K Venkataraman, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumorsE M Newman, M Carroll, S A Akman, et al.
Pageof 27